High-grade neuroendocrine carcinoma of the esophagus

High-grade neuroendocrine carcinoma of the esophagus is a rare and highly aggressive neoplasm belonging to the group of neuroendocrine neoplasms of the digestive system. It is characterized by poorly differentiated morphology and a high proliferative index, generally documented by Ki-67 and a high mitotic count. In modern classifications, these tumors mainly include small-cell neuroendocrine carcinoma and large-cell neuroendocrine carcinoma, entities that differ from well-differentiated neuroendocrine tumors in their biology, natural history and treatment strategies. The clinical picture is often dominated by rapid progression, early lymph-node and metastatic spread, and symptomatic presentation at an already advanced stage.

Clinically, the disease typically presents with symptoms caused by stenosis or involvement of the esophageal wall, particularly dysphagia, odynophagia, weight loss and retrosternal pain, which are often indistinguishable from those of epithelial esophageal neoplasms. Diagnosis requires endoscopy with multiple biopsies and rigorous pathologic assessment, in which immunohistochemistry for neuroendocrine markers and determination of differentiation and proliferative grade are essential to distinguish a high-grade neuroendocrine carcinoma from poorly differentiated carcinomas showing only focal expression of neuroendocrine markers and from mixed neoplasms. Radiologic and functional staging is essential from the outset because of the high probability of systemic disease.

Treatment is typically multimodal and is tailored to disease extent, performance status and the feasibility of locoregional control. In localized, potentially curable disease, local-control strategies involving surgery and radiotherapy are combined with systemic chemotherapy using platinum-etoposide or equivalent regimens employed for poorly differentiated neuroendocrine neoplasms. In metastatic disease, systemic therapy is the mainstay, with the principal aims of controlling disease and symptoms. Nutritional support and management of dysphagia-related complications are integral parts of treatment because they directly influence treatment tolerance and efficacy.

The epidemiology of high-grade neuroendocrine carcinoma of the esophagus is defined by its rarity, with frequency estimates varying among case series and registries, partly because of historical differences in diagnostic criteria and overlap with poorly differentiated esophageal carcinomas. It represents a small proportion of esophageal neoplasms but is clinically relevant because of its marked aggressiveness and the need for a treatment approach distinct from that used for squamous cell carcinomas and adenocarcinomas. Anatomically, it more often involves the middle and distal esophagus and generally presents with symptoms.

Demographically, the disease occurs more frequently in adults and older people and, in several series, a higher prevalence in men has been reported, although the small numbers limit interpretation. Diagnosis often occurs at an advanced stage, both because of rapid growth and because early symptoms may be subtle and overlap with common esophageal disorders. A high proportion of patients have metastases at diagnosis, which has a decisive effect on prognosis.

The specific etiologic causes of high-grade neuroendocrine carcinoma of the esophagus have not been defined. In the absence of a demonstrated necessary and sufficient cause, attention focuses on risk factors associated with esophageal neoplasms in general and on determinants shared with high-grade carcinomas. Associations with tobacco smoking and alcohol consumption have been reported in several series, particularly in tumors with a small-cell phenotype and in settings with coexisting dysplasia or squamous cell carcinoma. This suggests that some cases may share pathogenetic pathways, although no specific causal relationship has been established for the poorly differentiated neuroendocrine component.

A proportion of patients may have mixed components or areas of non-neuroendocrine differentiation, resulting in mixed neoplasms in which risk factors and transformation mechanisms may reflect the complexity of chronically injured esophageal epithelium. Overall, the rarity of the entity limits the ability to define risk profiles useful for targeted prevention; diagnosis therefore remains primarily dependent on early recognition of symptoms and the appropriateness of the endoscopic and histologic work-up.

There are no dedicated screening programs or population-surveillance strategies for high-grade neuroendocrine carcinoma of the esophagus, mainly because of the rarity of the disease and the absence of noninvasive tests with adequate sensitivity and specificity. Even in settings in which endoscopy is used for other indications, specific early detection of this entity cannot be justified because the diagnostic yield would be very low.

In clinical practice, early identification depends on attention to alarm features that warrant endoscopy, including progressive dysphagia, unintentional weight loss, unexplained iron-deficiency anemia, gastrointestinal bleeding, persistent odynophagia or retrosternal pain. In these situations, endoscopy is not performed to screen for neuroendocrine carcinoma but as an appropriate investigation for suspected organic esophageal disease, with extensive biopsy sampling of lesions.

In patients who have already been diagnosed and treated with curative intent, surveillance is not intended as screening but as timely identification of local or systemic recurrence, integrating clinical assessment, periodic imaging and management of nutritional and functional sequelae. In patients with advanced disease receiving systemic treatment, follow-up focuses on treatment response and toxicity, with particular attention to worsening dysphagia and treatment-related infectious or hematologic complications.

Overall, the most rational strategy remains symptom-guided diagnosis based on alarm features, with appropriate use of endoscopy and biopsy when indicated; population surveillance is neither sustainable nor supported by evidence.

The biology of high-grade neuroendocrine carcinoma of the esophagus lies within the spectrum of poorly differentiated neuroendocrine neoplasms of the gastroenteropancreatic tract, which are characterized by rapid growth, high genomic instability and early metastatic capacity. Conceptually, these neoplasms are distinct from high-grade well-differentiated neuroendocrine tumors because their clinical behavior and treatment sensitivity follow different trajectories that more closely resemble those of high-grade carcinomas. Pathogenesis may involve transformation of epithelial cells with acquisition of a neuroendocrine program or evolution from precursors with neuroendocrine potential; in a proportion of cases, the presence of mixed components suggests tumor plasticity and a common origin with non-neuroendocrine carcinomas.

At the molecular level, poorly differentiated neuroendocrine carcinomas often show alterations in genes controlling the cell cycle and genomic stability, with frequent inactivation of tumor-suppressor pathways and profiles that partly resemble those of small-cell carcinomas arising at other sites. This biological complexity makes complete pathologic assessment important because correct identification of the diagnostic category directly guides chemotherapy selection and planning of locoregional control.

Histologically, two principal phenotypes are recognized. Small-cell neuroendocrine carcinoma consists of small cells with scant cytoplasm, finely granular chromatin and frequent necrosis, together with high mitotic activity. Large-cell neuroendocrine carcinoma contains larger cells, conspicuous nucleoli and organoid or trabecular architecture, while remaining poorly differentiated and highly proliferative. In both types, quantification of Ki-67 and the mitotic count is crucial for establishing high grade and distinguishing these carcinomas from well-differentiated tumors.

Pathologic features defining high-grade neuroendocrine carcinoma

• Poorly differentiated morphology with necrosis and high mitotic activity.
• A typically high Ki-67 index, supporting high-grade classification.
• Expression of neuroendocrine markers, particularly synaptophysin and chromogranin, with INSM1 support in selected settings.
• Assessment for a possible mixed component because mixed neoplasms have diagnostic and therapeutic implications.

The esophageal microenvironment and anatomic location influence the mode of clinical presentation, with a rapid effect on the lumen and swallowing function. The tendency toward early lymphatic spread is reflected in frequent lymph-node involvement even in apparently limited tumors. Initial staging must therefore be accurate, and the treatment approach must account from the outset for the probability of occult systemic disease.

The clinical manifestations of high-grade neuroendocrine carcinoma of the esophagus are often prominent and rapidly progressive but are not specific to the histologic subtype. The most typical symptom is worsening dysphagia, caused by endoluminal growth and infiltration of the wall, often associated with odynophagia and retrosternal pain. Weight loss may be marked and reflects both reduced food intake due to dysphagia and the systemic effects of the high-grade neoplasm, with a risk of malnutrition and sarcopenia already at presentation.

Regurgitation, nausea, cough due to microaspiration and worsening postprandial symptoms may occur. Tumor ulceration may cause occult bleeding with iron-deficiency anemia and fatigue, whereas hematemesis and melena are less common but possible. Some patients present with signs of metastatic disease, such as bone pain, respiratory symptoms, hepatomegaly or rapid deterioration in their general condition.

Endocrine-metabolic paraneoplastic syndromes can occur in high-grade neuroendocrine neoplasms but are less prominent at the esophageal site than the local and systemic symptoms caused by a high disease burden. When present, however, they require prompt recognition and correction because they can increase clinical frailty and reduce treatment tolerance.

Clinical presentations that most frequently lead to endoscopy

• Progressive dysphagia with reduced intake and weight loss.
• Persistent odynophagia and retrosternal pain.
• Unexplained iron-deficiency anemia or signs of gastrointestinal bleeding.
• Regurgitation, aspiration episodes and postprandial worsening.
• Rapid deterioration in general condition with suspicion of an aggressive neoplasm.

Physical examination may reveal pallor, signs of malnutrition and dehydration and, in advanced cases, findings consistent with metastases or complications. Overall, the clinical picture raises suspicion of organic esophageal disease but cannot distinguish the histologic subtype, making endoscopic and histologic confirmation and early systemic staging indispensable.

The diagnostic work-up for high-grade neuroendocrine carcinoma of the esophagus begins with clinical suspicion of an esophageal neoplasm and follows a sequence aimed, in order, at histologic demonstration, definition of the neuroendocrine phenotype and grade, and complete staging. Suspicion typically arises in the presence of progressive dysphagia, weight loss, anemia or retrosternal pain, particularly when alarm features coexist and progression is rapid.

The decisive first-line examination is esophagogastroduodenoscopy, with careful assessment of the lesion and multiple deep biopsies. The endoscopic appearance is nonspecific and may resemble squamous cell carcinoma, adenocarcinoma, ulcerated lesions or polypoid masses. Sampling must be extensive to reduce the risk of incomplete diagnosis, particularly when mixed components are present or when the tumor is necrotic and friable. If the tissue is not representative or there is clinicopathologic discordance, repeat sampling or endoscopic techniques that provide a larger amount of tissue are appropriate.

Definitive diagnosis is pathologic and requires integration of morphology and immunohistochemistry. The neuroendocrine phenotype is confirmed by markers such as synaptophysin and chromogranin, with possible support from other markers in selected settings. High grade is established by necrosis, mitotic activity and a high Ki-67 index. It is essential to distinguish a true poorly differentiated neuroendocrine carcinoma from non-neuroendocrine carcinomas that focally express neuroendocrine markers because the therapeutic implications are substantial. When a mixed neoplasm is suspected, the report should describe its components and, whenever possible, estimate their proportions.

Once the diagnosis has been established, staging must be rapid and complete. Contrast-enhanced CT of the chest, abdomen and pelvis forms the basis of assessment to define locoregional extent and metastases. 18F-FDG PET is often useful in high-grade tumors because of their greater metabolic avidity, enabling identification of otherwise occult metastatic sites and guidance of biopsies from distant lesions. Endoscopic ultrasonography may help assess depth of invasion and characterize regional lymph nodes, with fine-needle sampling when the result would change the treatment strategy. Laboratory assessment is supportive and focuses on anemia, metabolic status, nutritional status and suitability for intensive treatment.

In summary, diagnosis is based on endoscopy with multiple biopsies, immunohistochemical confirmation of neuroendocrine differentiation, determination of proliferative grade, and anatomic and functional radiologic staging, followed by early multidisciplinary discussion.

Staging of high-grade neuroendocrine carcinoma of the esophagus is challenging because no universally accepted, entity-specific staging system exists. In clinical practice, disease extent is described through integrated assessment of local invasion, lymph-node involvement and distant metastases using CT, 18F-FDG PET and, when indicated, endoscopic ultrasonography and histologic confirmation of suspicious sites. In many settings, the TNM system for esophageal neoplasms is used as a descriptive language to communicate anatomic extent, while recognizing that the biology and clinical behavior of high-grade neuroendocrine carcinomas are often more aggressive than those of conventional epithelial carcinomas.

In the absence of a dedicated staging system, clinical series frequently use stratification based on the anatomic distribution of disease, conceptually analogous to the distinction among localized, regional and metastatic disease. This framework does not replace an official system but supports clear clinical communication and practical alignment with treatment decisions.

Practical classification of disease extent in high-grade esophageal neuroendocrine carcinoma

• Localized disease: lesion confined to the esophagus, with no evidence of pathologic lymph nodes or distant metastases.
• Regional disease: locoregional lymph-node involvement documented radiologically or histologically, without distant metastases.
• Metastatic disease: presence of distant visceral or bone metastases, with or without locoregional disease.

Prognosis is generally unfavorable and is strongly influenced by disease extent at diagnosis and the ability to achieve effective systemic control. The main prognostic factors include distant metastases, lymph-node burden, performance status, nutritional status and response to chemotherapy. In localized disease, integration of locoregional and systemic treatment can achieve remission, but the risk of recurrence remains high because of the probability of early micrometastases. In metastatic disease, the aim is disease control with improvement of symptoms and preservation of swallowing function and nutritional status, which directly influence quality of life and continuity of treatment.

Treatment of high-grade neuroendocrine carcinoma of the esophagus requires a multimodal approach in which systemic therapy is almost always central, even in apparently localized disease, because of the high probability of micrometastatic spread. The strategy is tailored to disease extent, resectability, comorbidities and nutritional frailty, with the aim of maximizing disease control and preserving swallowing function.

In potentially curable localized or locoregional disease, combinations of platinum-based chemotherapy with etoposide and locoregional treatment are considered. Locoregional treatment may include definitive or preoperative radiotherapy and, in selected patients, surgery after adequate staging and multidisciplinary assessment. The choice between definitive chemoradiotherapy and an approach including surgical resection depends on lesion location, technical feasibility, operative risk and response to initial therapy. The systemic component remains crucial because distant recurrence is common.

For metastatic disease, systemic therapy is the mainstay. Platinum-etoposide is commonly used as first-line treatment for poorly differentiated neuroendocrine neoplasms, with the aim of rapidly reducing tumor burden and improving symptoms, particularly dysphagia. After progression, options depend on the duration of response, clinical condition and availability of additional cytotoxic regimens or experimental strategies at specialist centers. Radiotherapy may be used palliatively for the primary lesion or symptomatic metastases, while selected endoscopic procedures may help control obstructive symptoms in appropriate settings.

Treatment objectives and options according to the clinical setting

• Localized disease: systemic chemotherapy integrated with locoregional control by radiotherapy and, in selected patients, surgery after multidisciplinary assessment.
• Regional disease: chemoradiotherapy as the principal treatment axis, with surgery reserved for selected cases after careful reassessment of response and extent.
• Metastatic disease: systemic chemotherapy as the mainstay, palliative radiotherapy and supportive interventions for dysphagia and pain.
• Nutritional support: dietary interventions, enteral nutrition when indicated, and correction of anemia and metabolic abnormalities to maintain treatment continuity.

Supportive management is an integral part of treatment. Dysphagia and malnutrition require early nutritional care, often with dietetic involvement and, when necessary, enteral nutrition. Control of anemia, pain, and infectious or hematologic complications related to chemotherapy influences the ability to complete treatment cycles and overall efficacy. In patients with advanced disease, early integration of palliative care improves symptom control and supports treatment decisions consistent with realistic goals of care.

Follow-up and post-treatment surveillance for high-grade neuroendocrine carcinoma of the esophagus must be individualized because the rarity of the disease limits the availability of dedicated standardized protocols and the risk of systemic recurrence is high. In general, surveillance combines clinical assessment, laboratory monitoring focused on toxicity and nutritional status, and periodic imaging to identify recurrence or progression.

In patients treated with curative intent, the first few years carry the highest risk. Clinical visits should assess dysphagia, pain, weight loss, signs of malnutrition and symptoms suggesting distant recurrence. Imaging with CT and, when appropriate, 18F-FDG PET is used to detect recurrence and metastases. Endoscopy is reserved for suggestive symptoms, suspected local recurrence or management of complications such as stenosis or persistent ulcers, recognizing that clinical and radiologic assessment often takes priority because of the high probability of systemic involvement.

In patients receiving systemic treatment for advanced disease, follow-up focuses on response assessment and early diagnosis of hematologic, renal, neurologic and infectious toxicities, with the frequency of evaluations tailored to the regimen and clinical course. In all settings, preservation of nutritional status and swallowing function is a central practical objective because it directly influences treatment tolerance and quality of life.

Long-term quality-of-life considerations in high-grade neuroendocrine carcinoma of the esophagus are dominated by the impact of dysphagia, the consequences of radiotherapy and surgery when performed, and the cumulative effects of chemotherapy. Even in patients who achieve disease control, the need for dietary adaptations, fear of recurrence and frequent follow-up can substantially affect daily life.

After locoregional treatment, swallowing difficulties, reflux, residual odynophagia or stenosis requiring endoscopic dilatation may persist. Long-term nutritional management often entails small, frequent meals, modified food consistencies, and monitoring of weight and body composition, with attention to sarcopenia and frailty. Swallowing rehabilitation and structured dietetic support reduce functional impairment and improve independence.

Chemotherapy may leave chronic sequelae, including peripheral neuropathy, persistent fatigue and reduced ability to work, while radiotherapy may cause xerostomia, taste disturbances and, in some cases, fibrosis affecting esophageal function. Psycho-oncologic support is important because a diagnosis of a rare and aggressive neoplasm is associated with high levels of stress and uncertainty. Clear communication, continuity of care and multidisciplinary management promote adaptation and adherence to follow-up.

Overall, quality of life requires active, continuous management integrating symptom control, nutritional support, functional rehabilitation and prevention of late complications alongside oncologic monitoring.

Complications of high-grade neuroendocrine carcinoma of the esophagus result from local progression, systemic dissemination and treatment effects. Locally, the most frequent and clinically consequential complication is obstruction with severe dysphagia, dehydration and malnutrition, sometimes accompanied by aspiration and pneumonia. Tumor ulceration may cause occult bleeding with anemia or clinically significant hemorrhage. In advanced stages, metastases can cause organ failure and general deterioration with cachexia and pain.

Complications of locoregional treatment include post-radiotherapy stenosis, esophagitis, odynophagia, fistulas in selected settings, and surgical complications after resection, such as anastomotic leak, infections and respiratory complications. Pre-existing nutritional vulnerability increases the risk of complications and delays recovery, making intensive support essential even before treatment begins.

• Chemotherapy toxicity: myelosuppression with neutropenia and infection risk, nausea and vomiting, nephrotoxicity and neuropathy depending on the drugs used.
• Radiotherapy complications: acute esophagitis, late stenosis, persistent odynophagia and secondary nutritional impairment.
• Nutritional complications: weight loss, sarcopenia, micronutrient deficiencies and frailty, often worsened by dysphagia and treatment toxicity.

Prevention and management of complications are based on early nutritional assessment, correction of anemia and metabolic abnormalities, close monitoring during chemotherapy and radiotherapy, and multidisciplinary integration involving the gastroenterologist, dietitian, oncologist and radiation oncologist. In patients with advanced disease, early integration of palliative care improves symptom control and supports treatment decisions consistent with realistic goals of care.